GRAIL: GRAIL, Inc. and Athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri? Multi-Cancer Early Detection Test

GRAIL, Inc. announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution. Integration with athenaCoordinatorCore will allow over 160,000 U.S. clinicians on the athenahealth network toopt in to more seamlessly order Galleri directly in the EHR, reducing additional ordering steps. After the clinician's order is placed, the patient can take the Galleri test kit to a blood draw appointment. The Galleri test results will be made available automatically in the patient chart, reducing manual entry and administrative burden for the clinician's practice. Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique "fingerprint" of cancer. With a single blood draw, the Galleri test screens for the "fingerprint" of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today. It can also provide doctors with information on the cancer's origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings. GRAIL, Inc. announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution. Integration with athenaCoordinatorCore will allow over 160,000 U.S. clinicians on the athenahealth network toopt in to more seamlessly order Galleri directly in the EHR, reducing additional ordering steps. After the clinician's order is placed, the patient can take the Galleri test kit to a blood draw appointment. The Galleri test results will be made available automatically in the patient chart, reducing manual entry and administrative burden for the clinician's practice. Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique "fingerprint" of cancer. With a single blood draw, the Galleri test screens for the "fingerprint" of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today. It can also provide doctors with information on the cancer's origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings.